ArticleVaccine2025

Feasibility of cohort event monitoring and assessment of reactogenicity and adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine recipients in Nigeria, 2021.

Omotayo Bolu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.